Employment of Artificial Intelligence Based on Routine Laboratory Results for the Early Diagnosis of Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33854961/
Objective: In order to enhance the detection rate of multiple myeloma and execute an early and more precise disease management, an artificial intelligence assistant diagnosis system is developed.
Cyclopamine sensitizes multiple myeloma cells to circularly permuted TRAIL-induced apoptosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33732371/
Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is a promising anti-myeloma drug prototype. The aim of the present study was to investigate the synergistic effects of cyclopamine and circularly...
-
Mark Fesler4yrInteresting pharmacologic study demonstrating dual agent inhibition of myeloma cells. Further work hopefully will be done to confirm that this is a clinically relevant pathway
A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33814917/
1 Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA. 2 Lymphoma Division, Department of Hematologic Oncology & Blood Disorders, Levine...
-
Mark Fesler4yrA very nice review of car T cell therapy as pertains to what are likely to be the most common indications in the very near future
Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33770485/
To our knowledge, no study has evaluated the quality of control groups in randomised controlled trials of multiple myeloma. We aimed to do a systematic review of randomised controlled trials...
-
Mark Fesler4yrKudos to the authors for a comprehensive review of a group of patients that often doesn’t get a critical analysis ....
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR
Source : https://ascopubs.org/doi/full/10.1200/JCO.20.01814
PURPOSE In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD)...
-
Mark Fesler4yrThis study adds to a growing literature base on use of mrd prognostically in myeloma ...it will be interesting to see if this translates into predictive utility as well